

Horizon Europe ISIDORE Integrated Services for Infectious Disease Outbreak Research,
Grant Agreement number 101046133

- **Duration of the project:** 24 February 2022 -
- **Link:** -
- **Summary:** ISIDORE will contribute to Europe’s readiness to any epidemic-prone pathogen through a global, integrated and preparedness-driven approach by providing free of charge access to cutting-edge resources and services to scientific user communities for supporting their research projects in the field of infectious diseases in “peaceful times” as well as during outbreaks or epidemics. The Consortium brings together 154 partners under the umbrella of INSTRUCT, EUBIOIMAGING, EUOPENSREEN, ECRIN, EATRIS, BBMRI, INFRAFRONTIER, EMBRC, ELIXIR, ERINHA, EVAg, VETBIONET, INFRAVEC, SONAR GLOBAL, TRANSVAC, MIRRI and EMERGEN

Tender of the European Medicine Agency (EMA) “Safety monitoring of COVID-19 vaccines in the EU”

- **Duration of the project:** 6 April 2021 – 5 April 2023
- **Link:** -
- **Summary:** Study protocol for Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection). Prospective cohort study in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy and people with prior SARS-CoV-2 infection).

Horizon 2020 EU-RESPONSE European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases, Research and Innovation programme,
Grant Agreement number 101015736, WP1: DisCoVeRy trial, WP2: EU-SolidAct platform trial

- **National coordinator:** prof. MVDr. Monika Halánová, PhD.
- **Duration of the project:** 1 July 2020 – 30 June 2025
- **Link:** <https://eu-response.eu/>

	DisCoVeRy	EU-SolidAct
Full title	Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults	European DisCoVeRy for Solidarity: an Adaptive Pandemic and Emerging Infection Platform Trial.
Summary	This study is an adaptive, randomized, open clinical trial to evaluate the safety and efficacy of possible therapeutic agents in hospitalized adult patients diagnosed with COVID-19. Trial is sponsored by Inserm. This protocol therefore describes a randomized, multicentre, double-blind, placebo-controlled DisCoVeRy study that tests the safety and the efficacy of AZD7442 in hospitalized patients with COVID-19.	EU-SolidAct is an Adaptive Platform Trial developed to evaluate drug interventions in hospitalized patients with COVID-19 and to facilitate a joint European response to future pandemics. The trial is sponsored by Oslo University Hospital, Norway. The first investigational medicinal product was baricitinib. BerGenBio’s AXL inhibitor, bemcentinib has been selected by an international expert group to be the second compound to

		be studied in the EU-SolidAct platform.
--	--	---

Horizon 2020 EOSC-Life Providing an open collaborative space for digital biology in Europe, EXCELLENT SCIENCE - Research Infrastructures, Grant Agreement number 824087

- **Duration of the project:** 1 March 2019 – 31 August 2023
- **Link:** <https://www.eosc-life.eu/>
- **Summary:** EOSC-Life brings together the 13 Biological and Medical ESFRI research infrastructures (BMS RIs) to create an open collaborative space for digital biology. The project will publish 'FAIR' data and a catalogue of services provided by participating RIs for the management, storage and reuse of data in the European Open Science Cloud (EOSC). This space will be accessible to European research communities.

Visegrad Fund Educational V4 platform for capacity building in oncology

- **Summary:** The main goal is to create a training center for clinical trial study coordinators, and creating a comprehensive educational syllabus for clinical trial research staff in oncology is the primary objective.

APVV PP-COVID-20-0064 Prevalence study on herd immunity SARS-CoV-2 in the population of Eastern Slovakia PREVCOVEAST

- **The national coordinator:** prof. MVDr. Monika Halánová, PhD.
- **Duration of the project:** 16 September 2020 – 31 December 2021
- **Summary:** The study presents an approach on how to solve the highly topical problem of monitoring the prevalence of the Slovak population with the SARS CoV 2 virus. The primary goal is to perform a cross sectional study on the representative population in Eastern Slovakia, to compare the accuracy (sensitivity and specificity), and the mutual interpretability of individual serological methods for antibody detection, and to carry out the follow up of patients who have been positively diagnosed.